Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05906576 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05906576 · ClinicalTrials.gov record · last posted 2025-05-22

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Name: Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients — clinical trial record (NCT05906576)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorTaizhou Mabtech Pharmaceutical Co.,Ltd

Started2023-09-21

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2023-06-13; most recent amendment 2025-05-19. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-04-09

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT05906576
Lead Sponsor	Taizhou Mabtech Pharmaceutical Co.,Ltd
Conditions	Crohn Disease
Enrollment	30 participants
Start Date	2023-09-21
Primary Completion	2026-11 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2025-05-22